except active substance. Active substance is not contained in placebo
Sponsors
Mc2 Therapeutics Limited
Conditions
Chronic Kidney Disease associated Pruritus
Phase 2
A Parallel-group (2-Arm), Randomized, Double-blind, 12-week Trial to Evaluate the Efficacy and Safety of
MC2-25 Cream and MC2-25 Vehicle in Subjects with Chronic Kidney Disease-associated Pruritus (CKD-aP)
WithdrawnCTIS2022-500044-38-00
Target: 48Updated: 2022-06-29
A Parallel-group (2-Arm), Randomized, Double-blind, 12-week Trial to Evaluate the Efficacy and Safety of
MC2-25 Cream and MC2-25 Vehicle in Subjects with Chronic Kidney Disease-associated Pruritus (CKD-aP)
CompletedCTIS2022-500044-38-01
Start: 2023-02-20End: 2024-02-02Target: 48Updated: 2023-08-28